Quantcast

Plavix Patient Sues After Suffering from Traumatic Bleeding Event Allegedly While Taking Plavix

August 20, 2012

Parker Waichman LLP has filed a lawsuit on behalf of a man who experienced hemorrhaging, allegedly due to the use of Plavix (clopidogrel). The lawsuit alleges that Plavix caused the bleeding and claims that the Defendants failed to fully inform users about the risks of taking the blood-thinning medication.

New York, NY (PRWEB) August 20, 2012

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit against Bristol-Myers Squibb Company, Sanofi-Aventis U.S., L.L.S., Sanofi US Services Inc., and Sanofi-Synthelabo, Inc. The suit, which was filed on July 26th in the Supreme Court of the State of New York, County of New York (Index No. 154919/2012), alleges that Plavix caused hemorrhaging in a Maryland man.

According to the Complaint, the Plaintiff took Plavix from approximately 2004 to 2011. Thereafter, he suffered an Epidural hematoma/hemorrhage along with severe and permanent injuries, physical impairment and disfigurement, pain and suffering, loss of enjoyment of life, and economic damages. The lawsuit alleges that the Plaintiff suffered these adverse events as a direct result of using Plavix.

Furthermore, the lawsuit claims that the Defendants engaged in negligent and wrongful misconduct with regards to marketing and selling Plavix, beginning with the drug´s approval in 1997. According to the lawsuit, Plavix was approved based on the results of a single study known as CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events.) Although the U.S. Food and Drug Administration (FDA) cleared the drug, the agency warned the Defendants against marketing Plavix as superior to Aspirin.

Despite the FDA´s orders, the lawsuit alleges that the Defendants promoted Plavix as a first-line therapy over Aspirin. The suit states, for instance, that the Defendants claimed Plavix was more effective at preventing ischemic events and more tolerable for the gastrointestinal system compared to Aspirin. However, research studies have called these claims into question. In 2005, the New England Journal of Medicine (NEJM) published a study showing that Plavix users had a significantly higher rate of recurrent ulcer bleeding compared to patients who took Aspirin with a heartburn pill. The following year, another study in the NEJM showed that a combination of Aspirin plus Plavix was not more effective than Aspirin alone at reducing blood clot, stroke and heart attack.

The lawsuit states that the Defendants´ unethical actions were driven by financial interest. According to the complaint, Plavix costs about $4 per day whereas Aspirin is as low as 4 cents a day. Plavix has generated $42.8 billion in revenue since it entered the market, with sales of $7.1 billion last year.

Parker Waichman LLP continues to offer free legal consultations to victims of alleged Plavix side effects, including:

  •         Cerebral hemorrhage
  •         Thrombotic Thrombocytopenic Purpura (TTP)
  •         Gastrointestinal bleeding
  •         Ulcers
  •         Internal bleeding
  •         Bone marrow damage
  •         Heart attack
  •         Stroke
  •         Death

If you or a loved experienced serious, life-threatening internal bleeding, heart attacks, strokes, or a blood disorder, and you believe Plavix is to blame, please contact their office by visiting the firm’s Plavix side effects page at yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:

Parker Waichman LLP

Gary Falkowitz, Managing Attorney

(800) LAW-INFO

(800) 529-4636

http://www.yourlawyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebplavixhemorrhage/082012/prweb9813710.htm


Source: prweb



comments powered by Disqus